DXC020 / Hangzhou DAC Biotech - LARVOL DELTA

DXC020, a novel anti-CD54 antibody conjugate with a functional linker, exhibits potent anti-tumor efficacy (AACR 2025) - "The identification of CD54 as a candidate gene in prostate tumors exposed to chronic cisplatin administration highlights its potential as a therapeutic target in cancer, including liver cancer. These promising results indicated that CD54-ADCs could become a viable candidate for targeted therapy against tumors expressing CD54, offering a new frontier in the treatment of various cancers, in particular for hepatocellular or hepatobiliary carcinoma, which still remains a global health challenge. The successful humanization of the antibodies, their effective internalization in tumor cells, and the robust cytotoxicity of the resulting DXC020 both in vitro and in vivo models, position the CD54-ADC as a promising candidate in further clinical study."

Clinical • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Genito-urinary Cancer • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Oral Cancer • Pancreatic Cancer • Prostate Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • ICAM1